The development of resistance to conventional treatment has led WHO to recommend the use of combination therapies containing artemisinin derivative (artemisinin-based combination therapies also known as ACTs). All of the following combination therapies are recommended if such resistance is suspected, except :
Artemether plus lumefantrine Artesunate plus quinine Artesunate plus pyrimethamine-sulfadoxine Artesunate plus mefloquine